Safe use of Interleukin-17 Inhibitors for Psoriasis and Psoriatic Arthritis in Two Patients with a History of Lymphoproliferative Disease

Stephen Sansone, Yasmin Amir, Mark G. Lebwohl

Research output: Contribution to journalArticlepeer-review

Abstract

Psoriasis and psoriatic arthritis are chronic, inflammatory, immune-mediated diseases that affect the skin and joints, respectively. The older systemic agents that have been used to treat these conditions are associated with many side effects, including an increased risk of malignancies, specifically lymphoma. In the last few years, there has been a wave of development of novel systemic biologic therapies to target psoriasis and psoriatic arthritis. While long-term safety data is lacking, the newer therapies targeting interleukins 12, 23, and 17 reveal a much more favorable side effect profile, specifically with regards to lymphoma. Here we report two cases of patients with psoriasis and psoriatic arthritis who had histories of lymphoma, both successfully treated with an interleukin-17 inhibitor without any recurrence or worsening of lymphoproliferative disease.

Original languageEnglish
Pages (from-to)256-259
Number of pages4
JournalSKIN: Journal of Cutaneous Medicine
Volume4
Issue number3
DOIs
StatePublished - 8 May 2020

Keywords

  • IL-17
  • biologic
  • lymphoma
  • psoriasis
  • psoriatic arthritis

Fingerprint

Dive into the research topics of 'Safe use of Interleukin-17 Inhibitors for Psoriasis and Psoriatic Arthritis in Two Patients with a History of Lymphoproliferative Disease'. Together they form a unique fingerprint.

Cite this